Collegium Pharma (COLL) - Market Cap to Net Income

Collegium Pharma - graphic logo of issuer COLL

Collegium Pharmaceutical generates revenue from protected opioids used to treat severe pain. However, stringent regulation and the onslaught of generics are creating pressure, while narrow specialization amplifies legal risks. This price-to-earnings trend on the GURU.Markets chart visualizes these factors, where the current metric is 20.50, helping investors assess the premium paid for the asset.

collegiumpharma.com (COLL): Price to Earnings Ratio from 07/04/2022 to 11/12/2026

Comprehensive metric breakdowns and analytics for Collegium Pharmaceutical Inc (COLL)

- share price and expert price forecast:
Price Performance Chart collegiumpharma.com|COLL - Analyst Consensus Forecast
- market capitalization indicators:
Market Valuation Collegium Pharmaceutical, Inc.|COLL - Enterprise Value
- business book valuation details:
Book Value per Share Collegium Pharmaceutical|COLL - Company Book Value|Market Value to Book Value collegiumpharma.com|COLL - Aggregate Company Assets
- debt and solvency information:
Total Debt to Equity Ratio Collegium Pharmaceutical|COLL - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Collegium Corp|COLL - Company Debts|Debts to Book Value Collegium Pharmaceutical, Inc.|COLL - Company Long-Term Debt|Company Short-Term Debt Collegium Pharmaceutical|Quick Liquidity collegiumpharma.com
- net income and valuation ratios data:
COLL - Net Profit|Expected Net Profit Collegium Pharmaceutical|COLL - P/E Multiple|Forward Price to Earnings Multiple Collegium Pharma|COLL - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Collegium Pharmaceutical, Inc.|COLL - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Collegium Pharmaceutical|COLL - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months collegiumpharma.com|COLL - Net earnings per share growth this year|Expected earnings per share trend next year Collegium Pharmaceutical
Comprehensive company analysis:COLL (collegiumpharma.com)
Signature product of Collegium Pharmaceutical

For Collegium Pharmaceutical (COLL), whose resilience is based on the inelastic demand for pain management medications, the P/E ratio serves as a measure of the market value of each unit of net profit. The current value of 20.50 in the context of the company's P/E ratio reflects the balance between expected FCF growth and market risks, allowing the investor to assess the degree of overpayment for the business's stable marginal flows.

Analysis of competing companies

INDV: Company Value to Net Income|P/E Multiple CRON|CGC: Market Cap to Net Income|P/E Multiple HITI (High Tide Corp)|P/E Multiple Aurora Cannabis, Inc. ACB|ACHV - Price to Earnings Ratio|Company Value to Net Income SKYE (skyebioscience.com)|Anebulo Pharmaceuticals, Inc. (ANEB) - Price to Earnings Ratio|Price to Earnings Ratio InterCure|NTRB (Nutriband Inc) - P/E Multiple|Price to Earnings Ratio Nasus Pharma, Ltd. (NSRX)|Price to Earnings Ratio IGC Pharma, Inc. (IGC)|MIRA - Market Cap to Earnings|Price to Earnings Ratio Flora Growth FLGC|IM Cannabis Corp - Price to Earnings Ratio|ADIL - Price to Earnings Ratio|ARTL: Price to Earnings Ratio|ENSC: P/E Multiple|Market Cap to Earnings Titan Pharmaceuticals, Inc. (TTNP)|GNLN (Greenlane) - P/E Multiple|INM - Market Cap to Net Income Ratio|P/E Multiple AKAN|Business Payback Period Enveric Corp|Bright Green Corporation - Price to Earnings Ratio|P/E Multiple Hempacco Co Inc. HPCO